REG - Agronomics Limited - Exercise of Warrants and TVR

AgronomicsAnnouncement

11/07/2023 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230711:nRSK6681Fa&default-theme=true

RNS Number : 6681F  Agronomics Limited  11 July 2023

11 July 2023

Agronomics Limited

("Agronomics" or the "Company")

Exercise of Warrants

Total Voting Rights

Agronomics Limited (AIM:ANIC), a leading listed company focused on cellular
agriculture, announces that pursuant to the receipt of notices for the
exercise of warrants, it is issuing new 1,590 Ordinary Shares with a nominal
value of £0.000001 each in the capital of the Company ("Shares") at a
subscription price of 30.0p per Share, and 246 new Ordinary Shares at a
subscription price of 28.5p. The Company has received gross proceeds of
£547.11

Application has been made for 1,836 Shares to be admitted to trading on AIM
("Admission"), with Admission expected to occur on or around 18 July 2023.

The Shares will rank pari passu with the existing Ordinary Shares, including
the right to receive all dividends and other distributions declared after the
date of their issue.

Following Admission of the Shares, the Company will have 993,153,870 ordinary
shares with a nominal value of £0.000001 each in issue with voting rights and
admitted to trading on AIM. This figure may then be used by shareholders in
the Company as the denominator for the calculation by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the share capital of the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on
cellular agriculture and cultivated meat. The Company has established a
portfolio of over 20 companies at the Pre-Seed to Series C stage in this
rapidly advancing sector. It seeks to secure minority stakes in companies
owning technologies with defensible intellectual property that offer new ways
of producing food and materials with a focus on products historically derived
from animals. These technologies are driving a major disruption in
agriculture, offering solutions to improve sustainability, as well as
addressing human health, animal welfare and environmental damage. This
disruption will decouple supply chains from the environment and animals, as
well as being fundamental to feeding the world's expanding population. A full
list of Agronomics' portfolio companies is available
at https://agronomics.im/
(https://clicktime.symantec.com/368cVqxx3R6vTFuHpf6MSE66Gi?u=https%3A%2F%2Fagronomics.im%2F)
.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from
cells, as opposed to raising an animal for slaughter, or growing crops. This
encompasses cell culture to produce cultivated meat and materials, and
fermentation processes that harness a combination of molecular biology,
synthetic biology, tissue engineering and biotechnology to massively simplify
production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally
derived from conventional agriculture is going to change dramatically. We have
already witnessed the first wave of this shift with the consumer adoption of
plant-based alternative proteins but today, we are on the cusp of an even
bigger wave of change. This is being facilitated by advances in cellular
agriculture. This change is necessary, given scientists claims that if we
maintain existing animal protein consumption patterns, then we will not meet
the Paris Agreement's goal of limiting warming to 1.5℃

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market
share will reach 35% by 2040. This combined with the Good Food
Institute's estimate that a US $1.8 trillion investment will be required in
order to produce just 10% of the world's protein using this technology, means
that we are on the cusp of a multi-decade flow of capital to build out
manufacturing facilities. Funding in the field of cellular agriculture is
accelerating, however still less than US$ 5 billion has been invested
worldwide since the industry's inception in 2016.

 

For further information please contact:

 

 Agronomics Limited                               Beaumont Cornish Limited  Canaccord Genuity Limited        Cenkos Securities Plc  Peterhouse Capital Limited  SEC Newgate
 The Company                                      Nomad                     Joint Broker                     Joint Broker           Joint Broker                Public Relations
 Richard Reed                                     Roland Cornish            Andrew Potts                     Giles Balleny          Lucy Williams               Bob Huxford

 Denham Eke                                       James Biddle              Harry Rees                       Max Gould              Charles Goodfellow          Anthony Hughes

                                                                            Alex Aylen (Head of Equities)    Michael Johnson
 +44 (0) 1624 639396                              +44 (0) 207 628 3396      +44 (0) 207 523 8000             +44 (0) 207 397 8900   +44 (0) 207 469 0936        agronomics@secnewgate.co.uk

 info@agronomics.im (mailto:info@agronomics.im)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBGGDRDXBDGXB